NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/02/2024
Back to search
Official data from USPTO
LP LIPTIS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
05/15/2026
Trademark type
Combined
Nice classes
5
Filing date
10/25/2012
Registration date
08/06/2013
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/02/2024
Last transaction
05/15/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
03/15/2004
First use in commerce
03/15/2004
Drawing code
3
Owner type
03
Owner location
Spring Valley, NY, US
Examiner
MARTIN, JENNIFER MCGARRY
Law office
M70
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the wording "LIPTIS Pharmaceuticals" where the word "LIPTIS" appears in blue capital letters above the word "Pharmaceuticals" in red initial capital lettering with a blue horizontal line between the two words. To the left of the wording is a blue circle containing the stylized, capital letters "LP" where the "L" is blue and the "P" is red. The white is not claimed as a feature of the mark and represents background or transparent areas.
Holders and representatives
Holders
LIPTIS PHARMACEUTICALS USA, INC.
LIPTIS PHARMACEUTICALS USA, INC.
Representatives
Michael J. Schwab Moritt Hock & Hamroff LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
A full line of pharmaceutical preparations for the treatment of osteoarthritissexual dysfunctionpain and inflammationtype 2 diabeteshyperlipidemiahypertensionenzyme deficiencydepressionGI hyperacidityhepatic diseasegastrointestinal diseaseelevated uric acid; pharmaceutical preparationsproton-pump inhibitors; antibiotic ointments for treatment of cuts and abrasions; muscle relaxants; surgical antiseptic foam; dietary and nutritional supplements for humans
Publications
History of USPTO decisions and trademark events.
47 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/02/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/02/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/02/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
08/07/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/06/2022
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
03/14/2020
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/14/2020
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
03/05/2020
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
09/14/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/13/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/05/2019
E815
TEAS SECTION 8 & 15 RECEIVED
08/05/2019
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/06/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/21/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
08/06/2013
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/25/2013
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/25/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/21/2013
PUBO
PUBLISHED FOR OPPOSITION
05/21/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/01/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/16/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/15/2013
XAEC
EXAMINER'S AMENDMENT ENTERED
04/15/2013
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/15/2013
GNEA
EXAMINERS AMENDMENT E-MAILED
04/15/2013
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/15/2013
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/12/2013
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/31/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/15/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/07/2013
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
03/07/2013
PAPER RECEIVED
03/04/2013
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/28/2013
GNFR
FINAL REFUSAL E-MAILED
02/28/2013
CNFR
FINAL REFUSAL WRITTEN
02/28/2013
ACEC
AMENDMENT FROM APPLICANT ENTERED
02/05/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2013
ALIE
ASSIGNED TO LIE
01/31/2013
PAPER RECEIVED
01/29/2013
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/23/2013
GNRT
NON-FINAL ACTION E-MAILED
01/23/2013
CNRT
NON-FINAL ACTION WRITTEN
01/23/2013
DOCK
ASSIGNED TO EXAMINER
01/16/2013
MDSC
NOTICE OF DESIGN SEARCH CODE MAILED
11/01/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/31/2012
NWAP
NEW APPLICATION ENTERED
10/29/2012
Continuous trademark protection
Get notified about every new filing that threatens LP LIPTIS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.